目的评价表皮生长因子受体酪氨酸激酶抑制剂(EGFR⁃ TKIs) 用于新辅助治疗的可行性,
疗效和安全性. 方法将86 例ⅢA 期EGFR 突变型肺腺癌患者按随机数表法分为2 组 …

Introduction Next-generation sequencing (NGS) diagnostics have shown clinical utility in
predicting survival benefits in patients with certain cancer types who are undergoing …

Background/Aim: We investigated efficacy differences for afatinib versus gefitinib in non-
small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) …

Introduction Mutations in the tyrosine kinase domain of the epidermal growth factor receptor
gene (EGFR) are key driver alterations in lung adenocarcinomas (ADCAs). Exon 19 …

Objective To evaluate survival following afatinib (AF) and erlotinib (ER) treatment in
advanced del19 lung adenocarcinoma (AD19LA) with asymptomatic brain metastasis (ABM) …

Background The expression of calcium signaling pathway molecules is altered in various
carcinomas, which are related to the proliferation and altered characteristics of cancer cells …

Cancer-associated deaths account for the second-highest mortality rates in the United
States. Primary modalities of treatment often include surgery, radiation, and chemotherapy …

Background: This study aimed to evaluate the efficacy, safety and prognostic factors of
icotinib as first-line treatment in advanced non-small cell lung cancer (NSCLC) patients with …

目的: 探讨深圳市164 例非小细胞肺癌患者组织样本中表皮生长因子受体(EGFR)
基因的突变情况. 方法: 采用华因康Pstar-ⅡA 基因测序仪, 基于边连接边测序的DNA …

Globally, lung cancer is by far the leading cause of death by cancer-which contribute to
2.094 million death-with the highest toll from cancer being 1.8 million. Currently, lung cancer …